Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer

Steven P Weitzman; Steven I Sherman

doi:10.1016/j.ecl.2018.10.009

Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer

Endocrinol Metab Clin North Am. 2019 Mar;48(1):253-268. doi: 10.1016/j.ecl.2018.10.009. Epub 2018 Dec 11.

Authors

Steven P Weitzman¹, Steven I Sherman²

Affiliations

¹ Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1461, Houston, TX 77030, USA.
² Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1461, Houston, TX 77030, USA. Electronic address: sisherma@mdanderson.org.

PMID: 30717907
DOI: 10.1016/j.ecl.2018.10.009

Abstract

Systemic therapy options have emerged for treatment of progressive, radioiodine-refractory differentiated thyroid carcinoma. Approved therapies that target tumor angiogenesis, lenvatinib and sorafenib, improve progression-free survival and, in an older subset, lenvatinib can prolong overall survival. Treatments based on targeting specific somatic genetic alterations are also available, which potentially also may prolong progression-free survival but are not yet approved for use by the Food and Drug Administration for this specific disease. More novel approaches that may benefit select patients include resensitization therapies that allow further radioiodine utilization and new immunotherapy concepts.

Keywords: Angiogenesis; Immunotherapy; MEK kinases; Mitogen-activated protein kinases; Protooncogene protein TRK; Receptor tyrosine kinase RET; TOR serine-threonine kinases; Thyroid neoplasms.

Publication types

Review

MeSH terms

Disease Progression*
Genetic Therapy / methods*
Humans
Immunotherapy / methods*
Protein Kinase Inhibitors / therapeutic use*
Thyroid Neoplasms / drug therapy
Thyroid Neoplasms / therapy*

Substances

Protein Kinase Inhibitors